Guidelines for ATC classification and DDD assignment - WHOCC

208
The DDDs are based on approved dose recommendations.
When establishing DDDs for combination products in the 50-series,
all analgesic components are taken into consideration if the amount
of each component is on a therapeutic level.
The DDD, expressed in UD, should normally not exceed the
approved dose recommendations for any of the components.
See list of DDDs for combination products, www.whocc.no.
N02AB Phenylpiperidine derivatives
Fentanyl patches are classified in this group whereas parenteral
formulations are classified in N01AH.
The transdermal DDD for fentanyl is based on the amount delivered
per 24 hours.
N02AC Diphenylpropylamine derivatives
Methadone and levacetylmethadol are classified in N07BC - Drugs used
in opioid dependence.
Dextropropoxyphene in combination with a muscle relaxant is classified
in M03B.
Different DDDs are assigned for different dextropropoxyphene
salts based on their different solubility.
N02AD Benzomorphan derivatives
N02AE Oripavine derivatives
High strength formulations (above 0.4 mg) of buprenorphine used in
opioid dependence are classified in N07BC.
N02AF Morphinan derivatives